Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PDS Biotechnology ( (PDSB) ) just unveiled an announcement.
On August 25, 2025, PDS Biotechnology announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial, which evaluated PDS0101 combined with Keytruda in patients with HPV16-positive head and neck squamous cell cancer. The trial showed a median overall survival of 39.3 months, significantly surpassing the standard of care, positioning PDS Biotech as a leader in addressing the unmet medical need for effective therapies in this rapidly growing cancer segment.
The most recent analyst rating on (PDSB) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.
Spark’s Take on PDSB Stock
According to Spark, TipRanks’ AI Analyst, PDSB is a Neutral.
PDSB’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. The company’s strong clinical progress and cash position are significant positives, but financial sustainability and valuation concerns due to ongoing losses and reliance on external funding temper the outlook. Technical indicators suggest some positive momentum, albeit with caution.
To see Spark’s full report on PDSB stock, click here.
More about PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The company is advancing its lead program in advanced HPV16-positive head and neck squamous cell cancers, developing its lead investigational targeted immunotherapy PDS0101 in combination with a standard-of-care immune checkpoint inhibitor.
Average Trading Volume: 475,002
Technical Sentiment Signal: Sell
Current Market Cap: $55.49M
Find detailed analytics on PDSB stock on TipRanks’ Stock Analysis page.